基本信息
views: 11
Career Trajectory
Bio
Centers to which I belong as researcher:
-From May 2017 to the present time: Group leader of "Research laboratory for molecular treatments
against cardiac fibrosis" FIBROHEART at the Institute of Biomedicine and Biotechnology of Cantabria IBBTEC, laboratory 03:01
- From Sep. 2008 to the present time: Professor of the University of Cantabria
-From February 2007 to the present time: Researcher's position collaborating with the Research Institute of the Hospital Marqués de Valdecilla IDIVAL.
One biomedical product patented: OPE nº P201700440/41/42/43
Current Interests:
The current interests of my group which is focus on the inhibition of fibrotic processes mainly in the myocardium using new biotechnological molecules, genetically modified system
RuizdelRio J,., Villar AV 2022 Pro-fibrotic role of inducible Hsp90α isoform in Hsp90α isoform in systemic sclerosis. J. Immunol. 21-00430-FLR1 IF=5.4
Groen J, Palanca A, Aires A Pereiro E (CA).(8/10). 2021. Correlative 3D cryo X-ray imaging reveals intracellular location and effect of designed antifibrotic protein–nanomaterial hybrids. Chem. Science. Ahead of print https://doi.org/10.1039/D1SC04183E. IF=9.825
Algeciras L, Palanca A, Maestro D, RuizdelRio J, Villar AV (CA). (5/5). 2021. Epigenetic alterations of TGFβ and its main canonical signaling mediators in the context of cardiac fibrosis. J Mol Cell Cardiol. Oct;159:38-47. IF= 5.315
Aires A, Maestro D, RuizdelRio J, Villar AV (CA). (9/10). 2020. Engineering multifunctional metal/protein hybrid nanomaterials as tools for therapeutic intervention and high-sensitivity detection. Chem. Science Dec 14;12(7):2480-2487. IF=9.825
García R...., Nistal F(CA) (6/9) 2020. Sex-Specific Regulation of miR-29b in the Myocardium Under Pressure Overload is Associated with Differential Molecular, Structural Remodeling in Mice and Patients with Aortic Stenosis. Cells.Mar 30;9(4):833. IF= 6.600
Russel A, Sneider A, Witwer K Vader P (CA). (31/36) 2019. Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs J Extracell Vesicles Nov 8;8(1):1684862. IF=25
-Biomarkers in disease March 2016 DOI 10.1007 / 978-94-007-7741-5_28-1
- 2015 SEC, FCVB 2016, SEBBM 2016, 2017, 2018
Mobility as a researcher:
Contracts in Universities, National and International Research Institutes: University of Barcelona, Würzburg University, Cultures Institute of Utrecht "Genomic Institute of the Novartis Research Foundation" California.
Pre-doctoral scientific training: Department of Biochemistry at the Complutense University of Madrid with Dr. Gavilanes as a student in the last years of the Chemical Sciences (Biochemistry specialty).
University of Utrecht, in the department of Enzimology of Dr. Verheij for the realization of a master of protein enzymology.
Predoctoral training:
Publication of 10 articles of high impact index, director of thesis Dr. Goñi F, Department of Biochemistry of the UPV. Topic: "liposomes and generation of second messengers mediated by phospholipases".
1- 2005 Biochemistry. Aug 30; 44 (34): 11592-600. 2-5 FEBS Lett. 579, 59-65. 3- 2003; Methods Enzymol 372: 3-19. 4- 2003 J Biol Chem Sep 26; 278 (39): 37169-74. 5- 2002 J Biol Chem Jul 5; 277 (27): 24090-102. 6- 2001 Mol Med Jul; 7 (7): 454-60. 7- 2001 FEBS Lett. 494, 117-120. 8-2000 Biochemistry 39, 14012-14018. 9-1999 FEBS Letters. Aug 20; 457 (1): 71-4. 10-1998 FEBS Letters 432, 150-154.
Stays in the University of Würzburg, article JBC nº 5 in list and regular collaborations with the Institute of Biomedical Investigations "Alberto Sols" Madrid, articles nº 2, 6, 9.
Postdoctoral period:
First postdoctoral period in the group of Biochemistry of Dr. Zorzano A, (Uniersity of Barcelona). Topic: "identification and characterization of DOR myocardial protein".
-PLoS One. 2007 Nov 21; 2 (11): e1183.
Second postdoctoral period to be selected as the best young Spanish scientist to investigate in the private projects of the GNF Norvartis California Research Institute. Junior investigator of Drug Discovery department of Tekturna research team (Aliskiren) drug for cardiovascular protection; Drug approved by the FDA in 2007. This experiment marks the course of my later investigations as Senior Investigator
Third postdoctoral period at the IDIVAL (Research Institute of the Hospital Marqués de Valdecilla, Cantabria) and contract as Professor of the Department of Physiology and Pharmacology at the University of Cantabria. In this period the translational study focuses on myocardial fibrosis, microRNAs involved, its detection in plasma and its signaling pathways in animal models and patients collaborating in different projects with Drs: Dr. Evangelista (RETICS), Dr. IZpisua-Belmonte (Salk Institute), Dr. Hurlé (UC), and Dr. Nistal (IDIVAL). See section C1 (publications in recent years).
Recognition of the University of Cantabria and the European and Spanish Societies of Cardiology in the form of economic awards
Research Interests
Papers共 44 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Jorge Ruizdelrio,Gabriela Guedes, Danielle Novillo, Elena Lecue,Ana Palanca,Aitziber L. Cortajarena,Ana V. Villar
THERANOSTICSno. 1 (2024): 176-202
BRITISH JOURNAL OF PHARMACOLOGY (2023): 84-85
Cited0Views0Bibtex
0
0
Journal of molecular and cellular cardiology (2021): 38-47
A Lupieri,C Brenner,Raquel García, Nf Smirnova,Nf Malet, Jf Arnal,Lo Martinez,Matthias P. Wymann,Emilio Hirsch,S Gayral,M Laffargue,F Remm,
BIOMARKERS IN CARDIOVASCULAR DISEASE, VOLS 1 AND 2pp.285-317, (2016)
Load More
Author Statistics
#Papers: 61
#Citation: 1466
H-Index: 22
G-Index: 38
Sociability: 6
Diversity: 0
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn